Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00189475 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds
A Phase 4 study of Upper Respiratory Infection, sponsored by Deborah Gentile.
- Completed
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT00189475: Completed Phase 4 study of Upper Respiratory Infection, sponsored by Deborah Gentile.
NCT00189475 is a Phase 4 study of Upper Respiratory Infection that has completed, run by Deborah Gentile. The registered enrollment target is 84 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00189475, a Phase 4 study of Upper Respiratory Infection, has completed, sponsored by Deborah Gentile.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Montelukast
Study Locations (1)
Pennsylvania
- Allegheny General Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
What the finished NCT00189475 record still lists
NCT00189475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Upper Respiratory Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00189475 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00189475 about?
NCT00189475 is a clinical study titled "Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds". Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.
What is the current status of trial NCT00189475?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2003-10. Estimated completion is 2007-07.
What conditions does trial NCT00189475 study?
This clinical trial studies the following conditions: Upper Respiratory Infection.
What interventions are being tested in trial NCT00189475?
The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT00189475?
This trial is sponsored by Deborah Gentile, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00189475 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Upper Respiratory Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00189475's enrollment target sits among peer trials
84 929th of 2000 higher than 1,064 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia